Karen McGuire

Company: BioMendics

Job title: Chief Executive Officer

Seminars:

Utilizing mTOR Inhibitors to Stabilize Intermediate Filaments in Epidermolysis Bullosa 12:00 pm

Examining the role of mechanistic target of rapamycin (mTOR) in Epidermolysis Bullosa to unveil the rationale behind mTOR inhibition Exploring mTOR inhibitor’s ability to degrade and remove mutant keratins through stimulation of autophagy The promise of BM-3103 in orphan diseases as a novel approach to treating unmet needsRead more

day: Day Two Clinical Track AM